POS-076 Serum Cystatin C as early marker for AKI of Patients after Coronary Angiography: a Prospective, Observational Study in Mexican population

Topete, L. Rizo; Alvarado-Villarreal, F.; Urrutia-Stamatio, B.; Garcia, MA

doi:10.1016/j.ekir.2022.01.085

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In COVID-19 patients, elevated levels of sCys C have been observed, which may indicate kidney damage or dysfunction. This study was done to evaluate sCys C level as a predictor of disease severity in Egyptian patients with COVID-19 infection [13] .…”

Section: Discussionmentioning

confidence: 99%

“…While increased blood levels of sCys C in COVID-19 patients are likely to suggest the presence of renal impairment, such as AKI, they may also be an indication of the patients' excessive systemic inflammatory and pro-oxidant condition [11] . In COVID-19 patients, sCys C levels may provide beneficial evidence about the presence of systemic inflammation and renal dysfunction and have a predictive value for AKI and death [12,13] .…”

Section: Serum Cystatin C [Scys Cmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic Significance of Serum Cystatin C as A Predictor of Severity in COVID-19 Infected Egyptian Patients

Ashry,

Elzefzafy,

Abouzahab

et al. 2023

International Journal of Medical Arts

View full text Add to dashboard Cite

Article informationBackground: may produce a systemic inflammatory state and multiorgan dysfunction, including renal damage. Biochemical and radiological tests are important in assessing disease severity and selecting therapeutic options. Serum cystatin C [sCys C] is involved in immunomodulatory responses in inflammatory conditions and infections, and it reflects changes in borderline renal function. The Aim of the work: Measurement of serum cystatin C levels in COVID-19 infected Egyptian participants as a predictor of the disease`s severity. Patients and Methods: This was an observational case-control study carried out on 80 participants, including 60 Egyptian COVID-19 patients and 20 healthy individuals as controls. All participants were investigated for laboratory, medical, and radiological features of COVID-19 as well as serum cystatin C. Patients were distributed into three categories according to illness severity; each group involved 20 patients: mild cases [group I], moderate cases [group II], and severe cases [group III].Results: Serum cystatin C levels were found to be higher in group III patients, with a highly statistically significant difference between groups. Group III patients had higher levels of CRP, D-dimer, serum urea, and creatinine, with a highly statistically significant difference between groups. With a cutoff of >9.6, there was a significant link between serum systatin C and the severity of COVID-19 disease, with 96.8% sensitivity and 100% specificity. Conclusion:The present study indicates that serum systatin C may serve as a tool for diagnosing potentially severe cases of COVID-19 infected Egyptian patients.

show abstract

Section: Discussionmentioning

confidence: 99%